Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

Lina Zhao, Man Xu, Wen Jiang, Haitao Pan, Jian Zang, Shanquan Luo, Jianhua Wang, Yongchun Zhou, Mei Shi

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). Results: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasisfree survival (DMFS), disease free survival (DFS) were 84.5%, 94.9%, 78.6% and 69.2%, respectively. The overall failure rate was 21.0% and distant metastasis occurred in 17.2% patients. Multivariate analyses showed that retropharyngeal and bilateral neck lymph node metastasis were significant prognostic factors for DFS and OS. Moreover, patients receiving both GP (gemcitabine+cisplatin) and TP (docetaxel+cisplatin) regimes had significantly higher DFS and OS compared with PF (cisplatin+5-FU) regime. GP regimes lead to significantly improved OS than TP/PF in some subgroup of patients. No severe toxicities were observed. Materials and Methods: We retrospectively analyzed stage III-IVb NPC patients treated between Jan 2006 and Dec 2014, with induction chemotherapy followed by concurrent chemoradiation (IC-CCRT). Statistical analyses were performed on survival and failure patterns. Conclusions: These results suggested IC-CCRT was safe and effective for NPCs from non-endemic region. The choice of induction regimen appeared to affect patient outcomes.

Original languageEnglish (US)
Pages (from-to)6763-6774
Number of pages12
JournalOncotarget
Volume8
Issue number4
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

    Fingerprint

Keywords

  • IMRT
  • Induction chemotherapy
  • Nasopharyngeal carcinoma
  • Non-endemic region
  • WHO II/III

ASJC Scopus subject areas

  • Oncology

Cite this